All Cancer articles – Page 17
-
NewsOvercoming chemotherapy resistance in pancreatic cancer
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
-
ArticleHow MMR-deficient colorectal cancers regulate their growth
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
-
NewsPredicting pancreatic cancer metastasis
Molecular, cellular and metabolic analyses of liver biopsies identified markers that may predict subsequent metastasis of pancreatic cancer.
-
NewsAI tool identifies high-risk subtype of endometrial cancer
The tool identified patients with high-risk disease, which normally goes unrecognised by traditional diagnostics.
-
NewsNovel inhibitor developed to combat HER2-positive breast cancer
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
-
NewsAssessing the risk of HCC with machine learning
A novel screening tool may increase the five-year survival rate of hepatocellular carcinoma patients to 90 percent.
-
NewsNew 3D genomic profiling technique details PanINs
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
-
ArticleNew algorithm forms atlas of histomorphological phenotypes
The algorithm can accurately diagnose cases of lung adenocarcinoma, determining structural features that are statistically most significant for assessing disease severity and likelihood of tumour recurrence.
-
ArticleA T cell receptor immunotherapy against a novel target
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
-
NewsMitigating fibrotic barriers in pancreatic cancer
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
-
ArticleeBook: Drop by drop: the future of liquid biopsy
The future of liquid biopsy is poised to revolutionise medical diagnostics and treatment. Explore the latest advancements and future prospects of liquid biopsy in our comprehensive eBook.
-
News
Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
-
NewsProteogenomics: finding targets for never-smoker lung cancer
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
-
NewsTargeting drug resistance in HER2-positive breast cancer models
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
-
ArticleLeveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
-
NewsReprogramming immune-suppressive macrophages in tumours
A novel drug, JHU083, turns into its active, glutamine-blocking form inside tumours, shrinking prostate and bladder cancers in mice.
-
ArticleImproving treatment responses to solid tumours with trispecific TCEs
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
-
NewsModelling the blood-brain barrier with organoids
The world’s first generation of human BBB organoids from hPSCs accurately replicated features of cerebral cavernous malformation.
-
ArticleTransomics’ impact on a promising liver cancer therapeutic
Using its AI-driven platform, Pepper Bio discovered a promising therapeutic for liver cancer. In this Q&A session with Jon Hu, CEO and co-founder of Pepper Bio, we dive into how the identification of two inhibitors led to a $135M in-licensing deal.
-
NewsOvarian cancer: CBR-5884 demonstrates promising antitumour effects
In assays and patient-derived organoids, the small molecule inhibitor CBR-5884 successfully treated epithelial ovarian cancer.